Desensitization to trimethoprim-sulfamethoxazole in a toxoplasmic encephalitis patient who was intolerant to conventional treatments

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 26; no. 3; pp. 289 - 293
• Main Authors: Miyata, Nobuyuki, Yoshimura, Yukihiro, Hikosaka, Kenji, Norose, Kazumi, Tachikawa, Natsuo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.03.2020
• Subjects: Adult; AIDS-Related Opportunistic Infections - diagnostic imaging; AIDS-Related Opportunistic Infections - drug therapy; AIDS-Related Opportunistic Infections - pathology; Atovaquone - therapeutic use; Brain - diagnostic imaging; Brain - pathology; Clindamycin - therapeutic use; Coccidiostats - administration & dosage; Coccidiostats - adverse effects; Coccidiostats - therapeutic use; Desensitization; Desensitization, Immunologic; Humans; Male; Sulfamethoxazole; Toxoplasmic encephalitis; Toxoplasmosis, Cerebral - diagnostic imaging; Toxoplasmosis, Cerebral - drug therapy; Toxoplasmosis, Cerebral - pathology; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage; Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use; CT; TE; Sulfamethoxazole; ARs; Desensitization; ART; MRI; Trimethoprim; AIDS; HMGB1; PCP; Toxoplasmic encephalitis

Toxoplasma gondii is an obligate intracellular protozoan that causes toxoplasmic encephalitis (TE) in immunocompromised patients. We describe a case of a 29-year-old Japanese man presenting with headache and vomiting. He had previously been diagnosed with human immunodeficiency virus infection. Magn...